Jennifer Willey
Nurse Practitioner · Lewes, DENPI 1104217595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $775 and has fallen 90.9% since, to $71 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$388
- Lilly USA, LLC$343
- Boehringer Ingelheim$211
- AstraZeneca$195
- AbbVie$180
- Astellas Pharma US Inc$179
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,69798%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $388 |
| Lilly USA, LLC | 23 | $343 |
| Boehringer Ingelheim | 16 | $211 |
| AstraZeneca(2 entities) | 11 | $195 |
| AbbVie | 11 | $180 |
| Astellas Pharma US Inc | 8 | $179 |
| Daiichi Sankyo Inc. | 9 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $151 |
| Amgen(2 entities) | 8 | $134 |
| GSK | 7 | $112 |
| Bayer | 6 | $97 |
| Exact Sciences | 5 | $96 |
| Pfizer | 5 | $81 |
| Lundbeck LLC | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Corcept Therapeutics | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Abbott | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Linus Health, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
How this compares
$2,763 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $84,300 |
| JardianceEmpagliflozin | 22 | $30,526 |
| FarxigaDapagliflozin Propanediol | 31 | $30,270 |
| MounjaroTirzepatide | 17 | $23,778 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,648 |
| EliquisApixaban | 13 | $15,377 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,057 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $6,814 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $5,779 |
| Atorvastatin Calcium | 332 | $5,409 |
| Rosuvastatin Calcium | 231 | $3,647 |
| Levothyroxine Sodium | 266 | $3,187 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,862 |
| VascepaIcosapent Ethyl | 12 | $2,788 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 18 | $2,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $388 | $84,30046 claims |
| AstraZenecaFarxiga, Symbicort | $195 | $36,04945 claims |
| Boehringer IngelheimJardiance | $211 | $30,52622 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $112 | $29,70529 claims |
| Lilly USA, LLCMounjaro | $343 | $23,77817 claims |
| PfizerEliquis | $81 | $15,37713 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $3,187266 claims |
| AbbVieSynthroid | $180 | $1,54028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Lewes
- Shelby HoganLewes$5K
- Jennifer ShadeLewes$4K
- Susan ParksLewes$3K
- Amanda CaputoLewes$3K
- Deborah TabulovLewes$2K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.